niacinamide has been researched along with Hypereosinophilic Syndrome in 6 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Hypereosinophilic Syndrome: A heterogeneous group of disorders with the common feature of prolonged eosinophilia of unknown cause and associated organ system dysfunction, including the heart, central nervous system, kidneys, lungs, gastrointestinal tract, and skin. There is a massive increase in the number of EOSINOPHILS in the blood, mimicking leukemia, and extensive eosinophilic infiltration of the various organs.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sorafenib was originally developed as a BRAF inhibitor, but our work demonstrates that sorafenib can also be used to treat FIP1L1-PDGFRA positive leukemia, demonstrating that new therapies to treat rare leukemias may be simply found by testing drugs that are already in use for the treatment of other diseases." | 1.36 | Identification and characterization of novel oncogenes in chronic eosinophilic leukemia and T-cell acute lymphoblastic leukemia. ( Cools, J, 2010) |
| "Chronic eosinophilic leukemia (CEL) is a rare myeloproliferative neoplasm characterized by the FIP1L1-PDGFRA fusion gene, variant PDGFRA fusions or other genetic lesions." | 1.35 | FIP1L1-PDGFRalpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRalpha T674I eosinophilic leukemia with single agent sorafenib. ( Beullens, E; Cools, J; Lierman, E; Marynen, P; Michaux, L; Pierre, P; Vandenberghe, P, 2009) |
| "Sorafenib was recently approved for the treatment of renal cell carcinoma." | 1.33 | Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant. ( Boogaerts, M; Cools, J; Folens, C; Lierman, E; Marynen, P; Mentens, N; Scheers, W; Stover, EH; Van Miegroet, H; Vandenberghe, P, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Salemi, S | 1 |
| Yousefi, S | 1 |
| Simon, D | 1 |
| Schmid, I | 1 |
| Moretti, L | 1 |
| Scapozza, L | 1 |
| Simon, HU | 1 |
| Lierman, E | 2 |
| Michaux, L | 1 |
| Beullens, E | 1 |
| Pierre, P | 1 |
| Marynen, P | 2 |
| Cools, J | 3 |
| Vandenberghe, P | 2 |
| Antoniu, SA | 1 |
| Metzgeroth, G | 1 |
| Erben, P | 1 |
| Martin, H | 1 |
| Mousset, S | 1 |
| Teichmann, M | 1 |
| Walz, C | 1 |
| Klippstein, T | 1 |
| Hochhaus, A | 1 |
| Cross, NC | 1 |
| Hofmann, WK | 1 |
| Reiter, A | 1 |
| Folens, C | 1 |
| Stover, EH | 1 |
| Mentens, N | 1 |
| Van Miegroet, H | 1 |
| Scheers, W | 1 |
| Boogaerts, M | 1 |
1 review available for niacinamide and Hypereosinophilic Syndrome
| Article | Year |
|---|---|
Novel therapies for hypereosinophilic syndromes.
Topics: Adrenal Cortex Hormones; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Ant | 2010 |
5 other studies available for niacinamide and Hypereosinophilic Syndrome
| Article | Year |
|---|---|
A novel FIP1L1-PDGFRA mutant destabilizing the inactive conformation of the kinase domain in chronic eosinophilic leukemia/hypereosinophilic syndrome.
Topics: Amino Acid Sequence; Benzamides; Benzenesulfonates; Chronic Disease; Drug Resistance; Humans; Hypere | 2009 |
FIP1L1-PDGFRalpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRalpha T674I eosinophilic leukemia with single agent sorafenib.
Topics: Aged; Animals; Benzenesulfonates; Blast Crisis; Blotting, Western; Cells, Cultured; Chronic Disease; | 2009 |
Identification and characterization of novel oncogenes in chronic eosinophilic leukemia and T-cell acute lymphoblastic leukemia.
Topics: Benzenesulfonates; Humans; Hypereosinophilic Syndrome; mRNA Cleavage and Polyadenylation Factors; Ni | 2010 |
Limited clinical activity of nilotinib and sorafenib in FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutation.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Benzenesulfonates; Chronic Disease; Drug | 2012 |
Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant.
Topics: Benzamides; Benzenesulfonates; Carcinoma; Cell Proliferation; Drug Evaluation, Preclinical; Drug Res | 2006 |